Genexine and NeoImmuneTech Announce Data Release for their Phase 1b/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in patients with Triple-negative Breast Cancer
ROCKVILLE, Md.--(BUSINESS WIRE)-- Genexine, Inc. and NeoImmuneTech, Inc. today announced the release of data for the dose escalation (DE) phase (Ph1b) of their Ph1b/2 study of GX-I7/NT-I7 (efineptakin alfa), a novel T cell amplifier, in combination with KEYTRUDA® (pembrolizumab), a leading checkpoint inhibitor (CPI), for the treatment of heavily pretreated patients with relapsed or refractory triple-negative breast cancer (TNBC). These data were shared in a poster presentation at the Society for Immunotherapy of Cancer (SITC) conference on November 9th, 2020.
The primary objectives of the DE phase of this study are to evaluate safety and tolerability of GX-I7/NT-I7 in combination with pembrolizumab and to determine the recommended phase 2 dose (RP2D). Two combination schedules of GX-I7/NT-I7 and pembrolizumab were evaluated: 1. Sequential administration of pembrolizumab + GX-I7/NT-I7, after cyclophosphamide (CPA) chemotherapy pre-treatment, and 2. Concurrent administration of pembrolizumab + GX-I7/NT-I7, without CPA chemotherapy pre-treatment.
As of September 30th, 2020, a total of 60 patients have been enrolled and treated in the DE phase of the study. Based on the encouraging efficacy and safety data, the standard dose of pembrolizumab plus 1,200 ug/kg GX-I7/NT-I7 concurrent administration without CPA chemotherapy pre-treatment has been selected as the RP2D. At this level, an objective response rate (ORR) of 28% has been observed.
Both combination schedules were well tolerated, and the most common treatment-related AEs were injection site reaction (n=44, 73.4%), rash (n=26, 43.4%), pyrexia (n=21, 35.0%), ALT/AST increase (n=19, 31.7%), GGT increase (n=12, 20.0%), myalgia (n=12, 20.0%) and nausea (n=11, 18.4%). GX-I7/NT-I7 was dosed up to 1,440ug/kg, however this level was not selected due to one dose-limiting toxicity observed with no additional clinical benefit noted.
“In addition to a well tolerated safety profile, we are pleased to see promising initial efficacy data at the RP2D in the dose escalation phase of this combination study,” said Jung Won Woo, Ph.D., Executive Vice President and Head of Research Institute at Genexine. “We look forward to completing the phase 2 portion of the study (dose expansion phase) and confirming the promising efficacy in a large dataset.”
NgocDiep Le, M.D., Ph.D., Executive Vice President and Chief Medical Officer of NeoImmuneTech, added: “Metastatic triple-negative breast cancer is an area of significant unmet need, making up 15-20% of breast cancers, and yielding progressively lower response rates and shorter survival after each subsequent relapse. These early efficacy signals in the dose escalation phase of our trial are encouraging and suggest that we may be able to provide a much needed chemo-free treatment option for these patients in dire need.”
Additional information on the trial can be found on www.clinicaltrials.gov using the identifier NCT03752723.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.
About GX-I7/NT-I7 (efineptakin alfa)
GX-I7 (Genexine Code Name) / NT-I7 (NIT Code Name) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). GX-I7/NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. GX-I7/NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and complemented by a strong executive team with rich industry experience at companies such as Novartis, BMS, GSK, Pfizer, Amgen, Eli Lilly, MedImmune/AstraZeneca and PwC. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.
Genexine, Inc., listed on KOSDAQ (095700) since 2009, is a leading and innovative Korean biotech company with proprietary novel long-acting biologics and immunotherapeutic DNA vaccine technologies. Company’s mission is to develop novel drugs to save lives of those who suffer from incurable diseases. Genexine has robust development pipeline portfolio which includes novel immunotherapeutic drug (GX-I7), cervical cancer vaccine (GX-188E), growth hormone (GX-H9), COVID-19 DNA vaccine, and therapeutics. GX-I7 is currently in several clinical tirals internationally targeting several cancer types as mono or combination therapy with global pharma companies. GX-188E, a therapeutic DNA vaccine for HPV-associated diseases is under Phase 2 trial in combination with Keytruda. Genexine is developing both preventive DNA vaccine candidate and therapeutics medicine for SARS-CoV-2, which causes Covid-19. Genexine has over 160 employees, located in Pangyo Techno Valley near Seoul metro area. Please visit www.genexine.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005341/en/
Source: NeoImmuneTech, Inc.
View this news release online at: